LTR Pharma (ASX:LTP) has announced that the first patients have received SPONTAN®, a nasal spray treatment for erectile dysfunction (ED), under the Therapeutic Goods Administration (TGA) Special Access Scheme.
- First patients receive SPONTAN® under the TGA Special Access Scheme
- Demonstrates potential for SPONTAN® in an unmet fast-acting, on-demand erectile dysfunction treatment market
- Internationally recognised Key Opinion Leader now actively engaged in prescribing SPONTAN®
- Enables strategic market introduction and collection of real-world data
- Platform to share experiences at international conferences and scientific publications.
LTR Pharma Chairman, Lee Rodne said: “The use of SPONTAN® under the early access program marks a watershed moment for LTR Pharma. It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential to address a high unmet need for a fast and on-demand ED treatment and allows for hands-on, real-world experience with SPONTAN®.”